Linda K. Myers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Linda K. Myers has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Andrew H. Kang
Department of Medicine, University of Tennessee, Memphis TN, 38163, USA
5 shared publicationsJohn M. Stuart
Department of Medicine, University of Tennessee, Memphis TN, 38163, USA
5 shared publicationsYoshihiko Sakurai
Department of Medicine, University of Tennessee, 956 Court Avenue, Memphis, TN 38163, USA
4 shared publicationsBo Tang
Department of Medicine, University of Tennessee, Memphis TN, 38163, USA
3 shared publicationsB. Tang
2 shared publications- David Douglass Brand
Research Service, Memphis VA Medical Center, Memphis, TN, USA
2 shared publications
Latest Publications
- 31 October 2009
- Published by Elsevier in Clinical Immunology
- Vol. 133 (1) , 145-153
T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk
- 31 October 2009
- Published by Elsevier in Clinical Immunology
- Vol. 133 (1) , 145-153
T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk
- 1 January 2007
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 27 (4) , 345-356
PART III. AutoimmunityAn Altered Peptide Ligand of Type II Collagen Suppresses Autoimmune Arthritis
On the basis of the hypothesis that immunity to type II collagen (CII) contributes to joint inflammation, our goal is to develop an immunotherapy capable of selectively blocking immunity to a particular autoantigen without interfering with the beneficial functions of the immune system. CII is the major protein component of articular cartilage and autoimmunity to CII is strongly associated with rheumatoid arthritis in man. Our laboratory has previously identified a region of type II collagen (CII), CII245-270 that contains a prominent T-cell epitope in the immune response to CII. Residues critical to the I-Aq-restricted presentation of this determinant have been characterized. When synthetic analog peptides were developed that contain site-directed substitutions in critical positions, we found that that CII245-270 (A260, B261, N263) (A9), profoundly suppressed collagen-induced arthritis. When DBA/1 mice were coimmunized with CII and the analog peptide, the incidence and severity of arthritis was greatly reduced concordant with the humoral immune responses to CII. Moreover, the suppression could be transferred with A9-immune spleen cells and was accompanied by a Th2-type cytokine profile. When we compared T-cell signals in response to A9 to those of wild-type (WT) peptide, we found that APCs prepulsed with WT peptide induced strong phosphorylation of both TCR zeta chain and Zap-70, while A9 did not. Since T cells clearly respond to A9 with cytokine secretion, we hypothesize that A9 induces an alternate signaling pathway and we speculate that this pathway involves phosphorylation of Syk, a kinase ordinarily utilized by B cells. Activation of this alternative pathway is a novel observation and may represent an important means by which the phenotype of the responding T cell is altered. Elucidation of the mechanism by which A9 prevents arthritis may lead to development of novel immunotherapeutic approaches to antigen specific treatment of autoimmunity.
- 1 January 2007
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 27 (4) , 345-356
PART III. AutoimmunityAn Altered Peptide Ligand of Type II Collagen Suppresses Autoimmune Arthritis
On the basis of the hypothesis that immunity to type II collagen (CII) contributes to joint inflammation, our goal is to develop an immunotherapy capable of selectively blocking immunity to a particular autoantigen without interfering with the beneficial functions of the immune system. CII is the major protein component of articular cartilage and autoimmunity to CII is strongly associated with rheumatoid arthritis in man. Our laboratory has previously identified a region of type II collagen (CII), CII245-270 that contains a prominent T-cell epitope in the immune response to CII. Residues critical to the I-Aq-restricted presentation of this determinant have been characterized. When synthetic analog peptides were developed that contain site-directed substitutions in critical positions, we found that that CII245-270 (A260, B261, N263) (A9), profoundly suppressed collagen-induced arthritis. When DBA/1 mice were coimmunized with CII and the analog peptide, the incidence and severity of arthritis was greatly reduced concordant with the humoral immune responses to CII. Moreover, the suppression could be transferred with A9-immune spleen cells and was accompanied by a Th2-type cytokine profile. When we compared T-cell signals in response to A9 to those of wild-type (WT) peptide, we found that APCs prepulsed with WT peptide induced strong phosphorylation of both TCR zeta chain and Zap-70, while A9 did not. Since T cells clearly respond to A9 with cytokine secretion, we hypothesize that A9 induces an alternate signaling pathway and we speculate that this pathway involves phosphorylation of Syk, a kinase ordinarily utilized by B cells. Activation of this alternative pathway is a novel observation and may represent an important means by which the phenotype of the responding T cell is altered. Elucidation of the mechanism by which A9 prevents arthritis may lead to development of novel immunotherapeutic approaches to antigen specific treatment of autoimmunity.
- Open Access
- 18 September 2006
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (5) , R150
Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
Rheumatoid arthritis (RA) is an autoimmune disease associated with the recognition of self proteins secluded in diarthrodial joints. We have previously established that mice transgenic for the human DR genes associated with RA are susceptible to collagen-induced arthritis (CIA) and we have identified a determinant of type II collagen (CII263–270) that triggers T-cell immune responses in these mice. We have also determined that an analog of CII263–270 would suppress disease in DR1 transgenic mice. Because the immunodominant determinant is the same for both DR1 transgenic and DR4 transgenic mice, we attempted to determine whether the analog peptide that was suppressive in DR1 transgenic mice would also be effective in suppressing CIA in DR4 transgenic mice. We treated DR4 transgenic mice with two analog peptides of CII that contained substitutions in the core of the immunodominant determinant: CII256–276 (F263N, E266D) and CII256–270 (F263N, E266A). Mice were observed for CIA, and T-cell proliferative responses were determined. Either peptide administered at the time of immunization with CII significantly downregulated arthritis. Binding studies demonstrated that replacement of the phenylalanine residue in position 263 of the CII peptide with asparagine significantly decreased the affinity of the peptide for the DR4 molecule. In contrast, replacement of the glutamic acid residue in position 266 with aspartic acid or with alanine had differing results. Aspartic acid reduced the affinity (35-fold) whereas alanine did not. Both peptides were capable of suppressing CIA. With the use of either peptide, CII256–276 (F263N, E266D) or CII256–270 (F263N, E266A), the modulation of CIA was associated with an increase in T-cell secretion of IL-4 together with a decrease in IFN-γ. We have identified two analog peptides that are potent suppressors of CIA in DR4 transgenic mice. These experiments represent the first description of an analog peptide of CII recognized by T cells in the context of HLA-DR4 that can suppress autoimmune arthritis.
- 18 September 2006
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (5) , R150
Open AccessAnalog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
Rheumatoid arthritis (RA) is an autoimmune disease associated with the recognition of self proteins secluded in diarthrodial joints. We have previously established that mice transgenic for the human DR genes associated with RA are susceptible to collagen-induced arthritis (CIA) and we have identified a determinant of type II collagen (CII263–270) that triggers T-cell immune responses in these mice. We have also determined that an analog of CII263–270 would suppress disease in DR1 transgenic mice. Because the immunodominant determinant is the same for both DR1 transgenic and DR4 transgenic mice, we attempted to determine whether the analog peptide that was suppressive in DR1 transgenic mice would also be effective in suppressing CIA in DR4 transgenic mice. We treated DR4 transgenic mice with two analog peptides of CII that contained substitutions in the core of the immunodominant determinant: CII256–276 (F263N, E266D) and CII256–270 (F263N, E266A). Mice were observed for CIA, and T-cell proliferative responses were determined. Either peptide administered at the time of immunization with CII significantly downregulated arthritis. Binding studies demonstrated that replacement of the phenylalanine residue in position 263 of the CII peptide with asparagine significantly decreased the affinity of the peptide for the DR4 molecule. In contrast, replacement of the glutamic acid residue in position 266 with aspartic acid or with alanine had differing results. Aspartic acid reduced the affinity (35-fold) whereas alanine did not. Both peptides were capable of suppressing CIA. With the use of either peptide, CII256–276 (F263N, E266D) or CII256–270 (F263N, E266A), the modulation of CIA was associated with an increase in T-cell secretion of IL-4 together with a decrease in IFN-γ. We have identified two analog peptides that are potent suppressors of CIA in DR4 transgenic mice. These experiments represent the first description of an analog peptide of CII recognized by T cells in the context of HLA-DR4 that can suppress autoimmune arthritis.
- 1 January 2006
- Published by Wiley in Immunology
- Vol. 117 (1) , 136-142
Molecular characterization of an arthritogenic collagen peptide interacting with I-Ar
Collagen-induced arthritis (CIA) is an autoimmune arthritis that can be elicited by the immunization of genetically susceptible strains of mice with type II collagen (CII). We have analysed the molecular interactions that occur between an arthritogenic T-cell determinant CII (442-457) and the murine class II susceptibility allele I-A(r). To determine which amino acid residues within the CII (442-457) sequence are responsible for binding to I-A(r), a soluble I-A(r):IgG2aFc fusion protein-peptide binding assay was developed. Various concentrations of analogue peptides were tested for their ability to compete with biotinylated CII (607-622) for binding to I-A(r), thereby establishing a relative comparison of the binding affinities among these analogues. Analogue peptides with substitutions at positions 447 (Ala --> Val), 448 (Gly --> Ala) and 451 (Gly --> Ala) bound poorly to the I-A(r) molecule. These data suggest that positions 447, 448 and 451 on CII are the major anchor points to I-A(r) molecules. In cytokine assays, only substitutions within positions 445-454 decreased the interferon-gamma production by T cells. These data narrow the core of the arthritogenic T-cell determinant to CII (445-454). Identification of the molecular interactions involved in T-cell recognition of CII should lead to antigen-specific means of inhibiting autoimmune arthritis.
- 1 January 2006
- Published by Wiley in Immunology
- Vol. 117 (1) , 136-142
Molecular characterization of an arthritogenic collagen peptide interacting with I-Ar
Collagen-induced arthritis (CIA) is an autoimmune arthritis that can be elicited by the immunization of genetically susceptible strains of mice with type II collagen (CII). We have analysed the molecular interactions that occur between an arthritogenic T-cell determinant CII (442-457) and the murine class II susceptibility allele I-A(r). To determine which amino acid residues within the CII (442-457) sequence are responsible for binding to I-A(r), a soluble I-A(r):IgG2aFc fusion protein-peptide binding assay was developed. Various concentrations of analogue peptides were tested for their ability to compete with biotinylated CII (607-622) for binding to I-A(r), thereby establishing a relative comparison of the binding affinities among these analogues. Analogue peptides with substitutions at positions 447 (Ala --> Val), 448 (Gly --> Ala) and 451 (Gly --> Ala) bound poorly to the I-A(r) molecule. These data suggest that positions 447, 448 and 451 on CII are the major anchor points to I-A(r) molecules. In cytokine assays, only substitutions within positions 445-454 decreased the interferon-gamma production by T cells. These data narrow the core of the arthritogenic T-cell determinant to CII (445-454). Identification of the molecular interactions involved in T-cell recognition of CII should lead to antigen-specific means of inhibiting autoimmune arthritis.
- 1 September 2004
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (9) , 3004-3011
Efficacy of modified recombinant type II collagen in modulating autoimmune arthritis
Objective Previous studies have shown that an analog peptide of the immunodominant T cell determinant of type II collagen (CII), i.e., CII256–276(N263, D266), was able to suppress the immune response to CII and the development of arthritis in DR1‐transgenic mice. The present study tested the hypothesis that introduction of the same amino acid substitutions into full‐length CII might improve the efficacy of the mutant collagen in achieving suppression of autoimmune arthritis. Methods Using recombinant technology, full‐length CII was modified, while the native conformation was retained. Two point mutations were introduced within the immunodominant T cell determinant to convert the F263 to N and E266 to D, using a baculovirus expression system that has previously been utilized in the production of recombinant CII (rCII). Results The mutant rCII(N263, D266) was capable of reducing the incidence and severity of arthritis as well as the antibody response to CII when administered to DR1‐transgenic mice that display susceptibility to collagen‐induced arthritis. More importantly, it was significantly more effective than the synthetic analog peptide, CII256–276(N263, D266). Its mechanism of suppression may be explained by the secretion of predominantly Th2 cytokines by the T cells immunized with rCII(N263, D266). Administration of rCII(N263, D266) was ineffective in suppressing arthritis in IL4−/− mice, suggesting that the profound suppressive effects of rCII(N263, D266) were mediated through the production of interleukin‐4. Conclusion These findings describe a promising specific immunotherapy for patients with DR1‐mediated autoimmunity to CII.
- 1 September 2004
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (9) , 3004-3011
Efficacy of modified recombinant type II collagen in modulating autoimmune arthritis
Objective Previous studies have shown that an analog peptide of the immunodominant T cell determinant of type II collagen (CII), i.e., CII256–276(N263, D266), was able to suppress the immune response to CII and the development of arthritis in DR1‐transgenic mice. The present study tested the hypothesis that introduction of the same amino acid substitutions into full‐length CII might improve the efficacy of the mutant collagen in achieving suppression of autoimmune arthritis. Methods Using recombinant technology, full‐length CII was modified, while the native conformation was retained. Two point mutations were introduced within the immunodominant T cell determinant to convert the F263 to N and E266 to D, using a baculovirus expression system that has previously been utilized in the production of recombinant CII (rCII). Results The mutant rCII(N263, D266) was capable of reducing the incidence and severity of arthritis as well as the antibody response to CII when administered to DR1‐transgenic mice that display susceptibility to collagen‐induced arthritis. More importantly, it was significantly more effective than the synthetic analog peptide, CII256–276(N263, D266). Its mechanism of suppression may be explained by the secretion of predominantly Th2 cytokines by the T cells immunized with rCII(N263, D266). Administration of rCII(N263, D266) was ineffective in suppressing arthritis in IL4−/− mice, suggesting that the profound suppressive effects of rCII(N263, D266) were mediated through the production of interleukin‐4. Conclusion These findings describe a promising specific immunotherapy for patients with DR1‐mediated autoimmunity to CII.
- 1 April 2004
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 327 (4) , 212-216
An Analog Peptide that Suppresses Collagen-Induced Arthritis
- 1 April 2004
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 327 (4) , 212-216
An Analog Peptide that Suppresses Collagen-Induced Arthritis
- Open Access
- 1 March 2004
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 172 (5) , 2970-2975
Relevance of Posttranslational Modifications for the Arthritogenicity of Type II Collagen
To establish the role of posttranslational modification in modulating the immune response to collagen, recombinant human type II collagen (rCII) was produced using a yeast expression system (rCIIpic) and a baculovirus expression system (rCIIbac). The biosynthesis of CII requires extensive posttranslational modification including the hydroxylation of prolyl and lysyl residues and glycosylation of selected hydroxylysyl residues. Amino acid analyses indicated that the rCIIbac was adequately hydroxylated at prolyl residues but underhydroxylated at lysyl residues and underglycosylated compared with tissue-derived CII, whereas rCIIpic was adequately hydroxylated at prolyl residues but unhydroxylated at lysyl residues and had no glycosylation. When DBA/1 mice were immunized with rCII, rCIIpic induced a lower incidence of arthritis than tissue-derived CII, whereas rCIIbac induced an intermediate level of arthritis. The severity of the arthritis was significantly lower in mice immunized with rCIIpic compared with mice immunized with tissue-derived CII, whereas that of rCIIbac was intermediate. These data indicate that the degree of lysine hydroxylation and glycosylation plays a role in the induction of arthritis. The recombinant collagens were then compared with tissue-derived CII when given as i.v. or oral tolerogens to suppress arthritis. Both recombinant collagens were less potent than tissue-derived CII, and this decrease in arthritis was associated with a decrease in Ab response to CII. These data suggest that the degree of glysosylation affects the immune response to CII, so that underglycosylated CII is less effective in the induction of arthritis and in its ability to suppress collagen-induced arthritis.
- 1 March 2004
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 172 (5) , 2970-2975
Open AccessRelevance of Posttranslational Modifications for the Arthritogenicity of Type II Collagen
To establish the role of posttranslational modification in modulating the immune response to collagen, recombinant human type II collagen (rCII) was produced using a yeast expression system (rCIIpic) and a baculovirus expression system (rCIIbac). The biosynthesis of CII requires extensive posttranslational modification including the hydroxylation of prolyl and lysyl residues and glycosylation of selected hydroxylysyl residues. Amino acid analyses indicated that the rCIIbac was adequately hydroxylated at prolyl residues but underhydroxylated at lysyl residues and underglycosylated compared with tissue-derived CII, whereas rCIIpic was adequately hydroxylated at prolyl residues but unhydroxylated at lysyl residues and had no glycosylation. When DBA/1 mice were immunized with rCII, rCIIpic induced a lower incidence of arthritis than tissue-derived CII, whereas rCIIbac induced an intermediate level of arthritis. The severity of the arthritis was significantly lower in mice immunized with rCIIpic compared with mice immunized with tissue-derived CII, whereas that of rCIIbac was intermediate. These data indicate that the degree of lysine hydroxylation and glycosylation plays a role in the induction of arthritis. The recombinant collagens were then compared with tissue-derived CII when given as i.v. or oral tolerogens to suppress arthritis. Both recombinant collagens were less potent than tissue-derived CII, and this decrease in arthritis was associated with a decrease in Ab response to CII. These data suggest that the degree of glysosylation affects the immune response to CII, so that underglycosylated CII is less effective in the induction of arthritis and in its ability to suppress collagen-induced arthritis.
- Open Access
- 12 December 2002
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (12) , 3369-3377
Peptide‐induced suppression of collagen‐induced arthritis in HLA–DR1 transgenic mice
Objective To identify peptides capable of altering the immune response to type II collagen (CII) in the context of HLA–DR. Methods Immunizing mice transgenic for the human HLA–DRB1*0101 immune response gene with CII elicits an arthritis (collagen-induced arthritis [CIA]) that resembles rheumatoid arthritis. We have previously identified an immunodominant determinant of CII, CII (263–270), recognized by T cells in the context of DR1. To produce synthetic peptides with the potential of disrupting the DR1-restricted immune response, synthetic analog peptides were developed that contain site-directed substitutions in critical positions. These peptides were used to treat CIA in DR1 transgenic mice. Results An analog peptide, CII (256–276, N263, D266), that inhibited T cell responses in vitro, was identified. When DR1 mice were coimmunized with CII and CII (256–276, N263, D266), the incidence and severity of arthritis were greatly reduced, as was the antibody response to CII. Moreover, CII (256–276, N263, D266) was effective in down-regulating the immune responses to CII and arthritis, even when administered 2 weeks following immunization with CII. Spleen and lymph node cells from CII-immunized mice cultured with CII (256–276, N263, D266) in vitro produced increased amounts of interleukin-4 (IL-4) compared with cells cultured with the wild-type peptide, CII (256–276). Furthermore, CII (256–276, N263, D266) was incapable of preventing arthritis in DR1 IL-4−/− mice (genetically deficient in IL-4). Conclusion These data establish that CII (256–276, N263, D266) is a potent suppressor of the DR-mediated immune response to CII. Its effect is mediated, at least in part, by IL-4. These experiments represent the first description of an analog peptide of CII recognized by T cells in the context of a human major histocompatibility complex molecule that can suppress autoimmune arthritis.
- 12 December 2002
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (12) , 3369-3377
Open AccessPeptide‐induced suppression of collagen‐induced arthritis in HLA–DR1 transgenic mice
Objective To identify peptides capable of altering the immune response to type II collagen (CII) in the context of HLA–DR. Methods Immunizing mice transgenic for the human HLA–DRB1*0101 immune response gene with CII elicits an arthritis (collagen-induced arthritis [CIA]) that resembles rheumatoid arthritis. We have previously identified an immunodominant determinant of CII, CII (263–270), recognized by T cells in the context of DR1. To produce synthetic peptides with the potential of disrupting the DR1-restricted immune response, synthetic analog peptides were developed that contain site-directed substitutions in critical positions. These peptides were used to treat CIA in DR1 transgenic mice. Results An analog peptide, CII (256–276, N263, D266), that inhibited T cell responses in vitro, was identified. When DR1 mice were coimmunized with CII and CII (256–276, N263, D266), the incidence and severity of arthritis were greatly reduced, as was the antibody response to CII. Moreover, CII (256–276, N263, D266) was effective in down-regulating the immune responses to CII and arthritis, even when administered 2 weeks following immunization with CII. Spleen and lymph node cells from CII-immunized mice cultured with CII (256–276, N263, D266) in vitro produced increased amounts of interleukin-4 (IL-4) compared with cells cultured with the wild-type peptide, CII (256–276). Furthermore, CII (256–276, N263, D266) was incapable of preventing arthritis in DR1 IL-4−/− mice (genetically deficient in IL-4). Conclusion These data establish that CII (256–276, N263, D266) is a potent suppressor of the DR-mediated immune response to CII. Its effect is mediated, at least in part, by IL-4. These experiments represent the first description of an analog peptide of CII recognized by T cells in the context of a human major histocompatibility complex molecule that can suppress autoimmune arthritis.